Fibrogen FG-3019

FGCL-3019-049 is a Phase 2a, open-label, single-arm study that will evaluate the safety, tolerability, and efficacy of FG-3019 in subjects with idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression. The study is sponsored by FibroGen, Inc., and is listed on the US NIH website www.ClinicalTrials.gov (search term NCT01262001). FG-3019 is a recombinant human monoclonal antibody that targets connective tissue growth factor (CTGF), which is believed to be a central mediator of the process of fibrosis and is implicated as a pathogenic factor in IPF. HRCT lung scans will be performed during the course of this year-long study to assess the effects of administration of FG-3019 on the interstitial lung infiltrates that are characteristic of IPF.